Mounjaro for Men: Evidence, Eligibility, Coverage

Mounjaro has no separate rule for men. It is approved for type 2 diabetes and heart risk. In SURMOUNT-1, people on Zepbound lost 20.9% of body weight on average, vs 3.1% on placebo.

Active ingredient: tirzepatide
How it is taken: weekly injection
Approved for: Type 2 diabetes and heart risk
Best result (SURMOUNT-1): 20.9% weight loss

Mounjaro in brief

How long it remains in your body

With a half-life of about 5 days, half leaves the body after 5 d, and about 3% remains at five half-lives, which equals 25 d.

Main trial weight loss

In SURPASS-1, people with type 2 diabetes lost 7.8 kg over 40 weeks, compared with 1 kg on placebo.

Price across time

In US dollars, monthly price points show the list price and self-pay offers. Each amount is read from the price page posted by the maker.

Sources: FDA label (DailyMed), healthsystemtracker.org, pricinginfo.lilly.com.

Who qualifies?

Mounjaro: who qualifies
Who sets the rule	Who qualifies
FDA label	Used with diet and exercise, it lowers blood sugar in adults and children with type 2 diabetes who are aged 10 or older.
FDA label	For adults at high risk with type 2 diabetes, it lowers the odds of a heart attack, stroke, or heart-related death.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	a diet and activity program comes first, lasting 6 months

Sources: FDA label (DailyMed), aetna.com.

Trial results for men

The studies enrolled adults with obesity or overweight without diabetes, and adults with obesity without type 2 diabetes.

Trials that used the same ingredient, tirzepatide
Trial	Medicine	Who took part	Length	People	Main result	Comparison
SURMOUNT-1	Zepbound	Adults with obesity or overweight, without diabetes	72 weeks	2,539	20.9% weight loss	3.1% on placebo
SURMOUNT-5	Zepbound	Adults with obesity, without type 2 diabetes	72 weeks	751	20.2% weight loss	Not listed

Sources: SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-5 (PubMed).

What is different for men?

For men: main Mounjaro label points
What changes	What the label says
Risk of Thyroid C-Cell Tumors	In rodents, it caused thyroid C-cell tumors. Whether it causes these tumors in people is not known. Do not use this if you or a family member has had medullary thyroid cancer (MTC), or if you have MEN 2.
Acute Pancreatitis	Can cause inflammation of the pancreas. Severe stomach pain that does not stop can sometimes spread to your back.

These details are taken from the FDA label (DailyMed).

These warnings are taken from the FDA label on DailyMed.

Coverage for men

Medicare Part D does not pay for a GLP-1 when it is used for weight loss alone.

When Medicaid covers weight-loss GLP-1s, prior authorization is the usual step.

Sources: humana.com, KFF.

Alternatives for men

GLP-1 medicines and men
Medicine	For men	How it is taken	Trial result
Mounjaro	Approved uses apply	weekly injection	Not listed
Ozempic	Approved uses apply	weekly injection	Not listed
Wegovy	Approved uses apply	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Approved uses apply	daily tablet	Not listed
Zepbound	Approved uses apply	weekly injection	20.9% weight loss
Foundayo	Approved uses apply	daily tablet	11.1% weight loss
Trulicity	Approved uses apply	weekly injection	Not listed
Saxenda	Approved uses apply	daily injection	7.4% weight loss
Victoza	Approved uses apply	daily injection	Not listed
Byetta	Approved uses apply	twice-daily injection	Not listed